Research: SHULTS and co-workers,

Listed in Issue 108

Abstract

SHULTS and co-workers, Department of Neurosciences, University of California, San Diego, La Jolla 92093-0662, USA, cshults@ucsd.edu, have conducted a pilot study of high-dosed coenzyme Q10 in patients with Parkinson's disease.

Background

The aim of this study was to bioavailability of coenzyme Q10 in patients with Parkinson's disease.

Methodology

17 patients with Parkinson's received an escalating dose of coenzyme Q10 going from 1200 to 3000 mg per day, with a stable dose of 1200 IU vitamin E per day. Plasma levels of coenzyme Q10 were measured at each dose.

Results

Thirteen of the subjects achieved the maximal dosage, and adverse events were typically considered to be unrelated to coenzyme Q10. The plasma level reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage.

Conclusion

These data suggest that in future studies of coenzyme Q10 in Parkinson's, a dosage of 2400 mg/day (with 1200 IU/day vitamin E) is an appropriate highest dosage to be studied.

References

Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Experimental Neurology 188(2): 491-494, Aug 2004.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

Scientific and Medical Network 2021

top of the page